@article{c868182a73df4ee18412b398ce0e2e66,
title = "Phase II study of Dovitinib in recurrent glioblastoma.",
author = "Mayur Sharma and Cathy Schilero and Peereboom, \{David M.\} and Hobbs, \{Brian Paul\} and Paul Elson and Stevens, \{Glen H.J.\} and Keith McCrae and Nixon, \{Andrew B.\} and Ahluwalia, \{Manmeet S.\}",
note = "Introduction Dovitinib is an oral, potent inhibitor of FGFR and VEGFR, and can be a promising strategy in patients with recurrent or progressive glioblastoma (GBM). Methods This was an open label phase II study of two arms: Arm 1 included anti-angiogenic na{\"i}ve patients with recurrent GBM and Arm 2 included patients with recurrent GBM that had progressed on prior anti-angiogenic therapy.",
year = "2019",
month = jul,
day = "11",
doi = "10.1007/S11060-019-03236-6",
language = "American English",
volume = "144",
journal = "Journal of neuro-oncology",
}